Here is your NEWS-Line for Pharmacists eNewsletter. For the latest news, jobs, education and blogs, bookmark our news page and job board or to take us everywhere with you, save this link to your phone. Also, enjoy the latest issue of NEWS-Line magazine, always free.
Addressing Gaps in Care, UArizona Health Sciences Offers Dual Pharmacy-Nursing Degree with Family Nurse Practitioner Add-on
Students at the University of Arizona Colleges of Nursing and Pharmacy soon will be offered the opportunity to simultaneously earn a Master of Science in Nursing, a Doctor of Pharmacy degree and a Family Nurse Practitioner certificate through a first-of-its-kind program created with the future of health care in mind.
The program responds to a national need for qualified health-care providers. The Association of American Medical Colleges projects a shortage of between 42,600 and 121,300 physicians by 2030, while demand for primary-care services is projected to increase at a more rapid pace than physician supply. An aging population, mixed with an exodus of primary care providers entering retirement, has stretched health-care resources thin, particularly for individuals living in rural or medically underserved areas that lack regular provider access.
“This unique program allows student
Read Full Article
Opioid Self-management Practices and Potential Safety Risks Among Patients with Cancer
Despite a national opioid crisis, prescribed opioid analgesics remain a viable option for pain management for patients with cancer. In effect, patients with cancer represent one of the few groups excluded from most state legislation and policy initiatives on prescribing opioids as well as from opioid stewardship programs of many health systems. However, little is understood about oncology patients’ opioid self-management practices and potential safety risk that may stem from these practices.
In new research from the University of Pennsylvania School of Nursing (Penn Nursing), investigators found that pain was the top concern identified by cancer patients in this study. However, they often could not take advantage of their prescribed opioid medications due to societal stigma and other opioid-related concerns. Patients with cancer in this study described using a number of practices to l
Read Full Article
Backed by Yale research, FDA approves new drug for advanced bladder cancer
The U.S. Food & Drug Administration (FDA) granted accelerated approval to the drug enfortumab vedotin (EV) to treat adult patients with advanced urothelial or bladder cancer. The approval is the direct result of a multi-institutional clinical trial led by Yale Cancer Center (YCC) and Smilow Cancer Hospital researchers, which demonstrated EV is an effective treatment for this deadly disease.
“This is very exciting progress as we haven’t had another therapy option for patients whose urothelial or bladder cancer has progressed after chemotherapy or immunotherapy,” said Daniel P. Petrylak, M.D., professor of medicine (medical oncology) and urology and co-director of the Cancer Signaling Research Program at YCC. “To my knowledge, this is most active single drug in urothelial cancer.” Petrylak was the senior investigator of a phase II clinical trial that studied the efficacy of EV for patien
Read Full Article
Precigen Receives FDA Orphan Drug Designation for PRGN-3006 UltraCAR-T™ in Patients with Acute Myeloid Leukemia (AML)
Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to PRGN-3006, a first-in-class investigational therapy using Precigen's non-viral UltraCAR-T™ therapeutic platform for patients with relapsed or refractory acute myeloid leukemia (AML) (clinical trial identifier: NCT03927261). Precigen announced in Q3 2019 that it had completed enrollment for the first cohort of this clinical trial and expects an initial data readout in the second half of 2020.
The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US. Medicines that receive the ODD designation may qualify for a number of incentive